Table 3 Mortality rates of patients with eGFR ≥ 30 who received levosimendan versus dobutamine alone
Outcomes | Event (%) | Levosimendan vs. dobutamine | ||
|---|---|---|---|---|
Levosimendan | Dobutamine | HR (95% CI) | P value | |
Before PSM patient numbers | 102 | 567 | ||
In-hospital mortality | 13 (12.7) | 61 (10.8) | 0.80 (0.43–1.51) | 0.491 |
5-day mortality | 3 (2.9) | 19 (3.4) | 0.87 (0.26–2.94) | 0.822 |
14-day mortality | 7 (6.9) | 38 (6.7) | 1.004 (0.45–2.25) | 0.992 |
30-day mortality | 13 (12.7) | 57 (10.1) | 1.23 (0.68–2.25) | 0.496 |
90-day mortality | 20 (19.6) | 83 (14.6) | 1.31 (0.80–2.13) | 0.285 |
180-day mortality | 22 (21.6) | 99 (17.5) | 1.20 (0.76–1.91) | 0.438 |
After PSM patient numbers | 82 | 145 | ||
In-hospital mortality | 9 (11.0) | 25 (17.2) | 0.37 (0.15–0.92) | 0.032 |
5-day mortality | 2 (2.4) | 10 (6.9) | 0.34 (0.07–1.60) | 0.173 |
14-day mortality | 5 (6.1) | 19 (13.1) | 0.44 (0.17–1.14) | 0.091 |
30-day mortality | 10 (12.2) | 28 (19.3) | 0.59 (0.28–1.23) | 0.160 |
90-day mortality | 16 (19.5) | 31 (21.4) | 0.85 (0.45–1.60) | 0.604 |
180-day mortality | 18 (22.0) | 36 (24.8) | 0.82 (0.46–1.46) | 0.501 |